Cagrilintide: How an Amylin Analog Combined with Semaglutide Targets Obesity Through Dual Brain Pathways

What the researchers found

Cagrilintide is a long-acting analog of amylin, which reduces appetite through both homeostatic (hunger-regulating) and hedonic (pleasure/reward) brain pathways. Combined with semaglutide (a GLP-1 receptor agonist that reduces appetite via hypothalamic GLP-1 receptors, increases insulin, reduces glucagon, and delays gastric emptying), the two peptides have separate but complementary mechanisms that produce additive appetite reduction.

Clinical trials have demonstrated promising weight loss with both cagrilintide alone and the cagrilintide-semaglutide combination, supporting further development of this dual-peptide approach for sustained weight management.

Why it matters

Obesity affects over a billion people worldwide and has limited pharmacological treatment options between lifestyle changes and bariatric surgery. While GLP-1 drugs like semaglutide have been transformative, many patients don't achieve sufficient weight loss with single-agent therapy. The cagrilintide-semaglutide combination targets obesity's heterogeneous pathophysiology more comprehensively, potentially helping more patients achieve clinically meaningful weight loss.

How the study worked

This is a review article summarizing the pharmacology of cagrilintide and semaglutide, their mechanisms of action, and clinical trial results. The review examines amylin biology, GLP-1 receptor agonist pharmacology, and the rationale for combining these two peptide classes for obesity treatment.

What this study cannot tell us

This review was published before large-scale phase 3 trial results were available for the combination therapy. Long-term safety and efficacy data beyond trial durations are not available. Whether the combination's benefits outweigh additional costs and potential side effects compared to semaglutide alone is not fully established. The additive effects described may not translate to proportionally greater weight loss in all patient populations. Injection burden increases with combination therapy.

How to read the evidence

This is a narrative review of clinical trial data and pharmacological evidence. While it provides a useful overview of the dual-peptide approach, it relies on available trial data which at the time of publication was primarily from earlier-phase studies.

When this study was published

Published in 2024, this review captures the clinical development of cagrilintide at a time when combination therapy trials were progressing. Regulatory decisions and additional trial results may have emerged since publication.

The bigger picture

The development of cagrilintide represents the next wave of peptide-based obesity treatment — moving from single-target to multi-target approaches. Just as cardiovascular medicine uses combination therapy to address multiple risk factors, obesity medicine is adopting the same principle with dual-peptide combinations. This approach acknowledges that obesity is not a single-mechanism disease, and the amylin-GLP-1 combination addresses both the biological drive to eat and the pleasure-seeking aspects of food consumption.

Questions still open

• How does the weight loss from cagrilintide-semaglutide compare to tirzepatide and other emerging multi-target obesity drugs?
• What is the durability of weight loss after stopping the cagrilintide-semaglutide combination?
• Will the combination therapy be cost-effective given that it involves two peptide drugs administered together?

Common questions

Read the original research

Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

Cardiology in review, 32(1), 83-90

Citation

D'Ascanio, Antonella M; Mullally, Jamie A; Frishman, William H. (2024). Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.. Cardiology in review, 32(1), 83-90. https://doi.org/10.1097/CRD.0000000000000513